Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ilacirnon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 known ✓ | P41597 | 12/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.84 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ilacirnon SCHEMBL31378455 | 1.00 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| Ilacirnon SCHEMBL127113 | 1.00 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| Ilacirnon SCHEMBL125684 | 1.00 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| Ilacirnon SCHEMBL29395065 | 1.00 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| Ilacirnon SCHEMBL125683 | 0.99 | CCR2 (0.98) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| SCHEMBL1188630 | 0.92 | CYP3A4 (0.84) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| SCHEMBL128785 | 0.92 | CYP2C9 (1.00) | CCR2CYP3A4CYP2C9JAK1 | |
| SCHEMBL127931 | 0.90 | CCR2 (0.81) | CCR2CYP3A4CYP2C9BRAFTNNI3K | |
| SCHEMBL12594931 | 0.90 | CCR2 (0.81) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| SCHEMBL130501 | 0.89 | CCR2 (0.81) | CCR2CYP3A4CYP2C9JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| EP-4525857-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2023225163-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4525857-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023225163-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023031308-A1 | CCR2 INHIBITORS | ARTICA THERAPEUTICS B.V. (NL) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | REN, AGT, FRS2 | CCR2 336/4885CYP3A4 4075/4885CYP2C9 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.